MY 5 FAVORITE STOCK OPPORTUNITIES🧵
MY 5 FAVORITE STOCK OPPORTUNITIES🧵
(No one is paying attention to n°5)
1) $TransMedics Group, Inc.(TMDX)$
Revolutionizing organ transplants, founder-led, stellar track record, and still cheap for its growth.
Natan's fair value: $174 (+48%)
Stock chart for Transmedics ($TMDX) displaying current price of 117.63 USD with 104.38 or 87.77 percent gain over past five years closed at 17 October 19:42 GMT after hours at 117.50 down 0.13 or 0.11 percent line graph showing price trend from 2023 to 2025 with time periods 1D 5D 1M 6M YTD 5Y and price scale from 0 to 200 disclaimer noted.
2) $Regeneron Pharmaceuticals(REGN)$
One of the best biotechs ever.
The company reinvests 40% of revenue in R&D, and excluding that, it trades at just 5x EV/FCF.
The market assumes those investments will never pay off, the track record says otherwise.
Natan's fair value: $786 (+36%)
Image
Everyone hates it, which makes it interesting.
Users and transactions per user are rising, operating income at record highs…
The only thing not rising? The stock price. But with the current buyback plan, that won’t last forever.
Natan's fair value: $107 (+59%)
Image
The greatest startup ever.
Ten years ago, this e-commerce didn’t even exist, now it sells $600B in products and generates $15B in annual FCF.
You’d think it’s expensive, but it trades at just 10x EV/FCF.
Natan's fair value: $176 (+37%)
Image
For whom haven't open CBA can know more from below:
🏦 Open a CBA today and enjoy privileges of up to SGD 20,000 in trading limit with 0 commission. Trade SG, HK, US stocks as well as ETFs unlimitedly!
Find out more here：
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
